The University of Chicago Header Logo

Olatoyosi Odenike

Concepts (456)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Myeloproliferative Disorders
18
2026
159
5.360
Why?
Leukemia, Myeloid, Acute
44
2026
850
5.260
Why?
Myelodysplastic Syndromes
28
2025
386
4.730
Why?
Primary Myelofibrosis
17
2026
72
3.490
Why?
Azacitidine
14
2025
152
2.710
Why?
Antineoplastic Combined Chemotherapy Protocols
37
2026
2666
2.270
Why?
Sulfonamides
12
2026
352
1.900
Why?
Hematopoietic Stem Cell Transplantation
22
2024
979
1.730
Why?
Leukemia, Myelomonocytic, Chronic
6
2025
25
1.580
Why?
Antineoplastic Agents
22
2023
2386
1.520
Why?
Protein Kinase Inhibitors
12
2026
642
1.430
Why?
Mutation
24
2026
4443
1.300
Why?
Transplantation Conditioning
18
2020
389
1.210
Why?
Hematologic Neoplasms
12
2022
384
1.200
Why?
Blast Crisis
5
2024
37
1.180
Why?
Stem Cell Transplantation
5
2018
196
1.150
Why?
Bridged Bicyclo Compounds, Heterocyclic
9
2026
112
1.080
Why?
Pyrimidines
13
2026
416
1.050
Why?
Benzamides
9
2025
260
1.030
Why?
Isocitrate Dehydrogenase
4
2025
63
1.030
Why?
Aged
74
2026
21986
0.950
Why?
Mitoxantrone
5
2020
65
0.940
Why?
Humans
139
2026
98799
0.940
Why?
Aged, 80 and over
38
2026
7461
0.890
Why?
Uridine
6
2026
57
0.860
Why?
Treatment Outcome
43
2026
9806
0.850
Why?
Middle Aged
73
2026
29642
0.830
Why?
Histone Deacetylase Inhibitors
5
2023
109
0.810
Why?
Bridged-Ring Compounds
2
2020
16
0.780
Why?
Aminopyridines
2
2021
54
0.770
Why?
Triazines
2
2021
55
0.770
Why?
Transplantation, Homologous
19
2020
1029
0.730
Why?
Male
81
2026
47475
0.730
Why?
Cytarabine
9
2023
218
0.710
Why?
Pyrazoles
6
2026
162
0.690
Why?
Janus Kinase 2
7
2021
59
0.680
Why?
Janus Kinase Inhibitors
2
2024
39
0.670
Why?
Female
79
2026
51997
0.640
Why?
Pyrrolidines
1
2020
61
0.630
Why?
Enzyme Inhibitors
3
2021
641
0.620
Why?
Depsipeptides
2
2010
30
0.600
Why?
fms-Like Tyrosine Kinase 3
8
2026
135
0.590
Why?
Antibiotics, Antineoplastic
2
2010
111
0.580
Why?
Leukemia
6
2022
310
0.560
Why?
Disease Management
5
2020
378
0.530
Why?
DNA Modification Methylases
1
2017
36
0.530
Why?
Benzimidazoles
2
2019
120
0.510
Why?
Adult
50
2025
29698
0.510
Why?
Mitogen-Activated Protein Kinase Kinases
2
2015
100
0.490
Why?
Disease Progression
10
2026
1621
0.490
Why?
Clinical Trials as Topic
5
2025
1128
0.480
Why?
Neoplasms
9
2023
3382
0.480
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
2025
445
0.460
Why?
Prognosis
17
2026
4139
0.460
Why?
Hydroxamic Acids
2
2017
53
0.460
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
2012
177
0.450
Why?
Antimetabolites, Antineoplastic
4
2024
246
0.440
Why?
Molecular Targeted Therapy
4
2020
331
0.420
Why?
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
2026
68
0.410
Why?
Gene Rearrangement
2
2025
175
0.400
Why?
Precision Medicine
4
2021
512
0.390
Why?
Cord Blood Stem Cell Transplantation
4
2016
91
0.380
Why?
Cell Transformation, Neoplastic
2
2015
466
0.380
Why?
Medical Oncology
4
2025
426
0.380
Why?
Eosinophilia
2
2014
87
0.380
Why?
Pulmonary Eosinophilia
1
2012
5
0.380
Why?
Receptor, Platelet-Derived Growth Factor alpha
1
2012
12
0.380
Why?
Hematopoiesis, Extramedullary
1
2013
14
0.380
Why?
Bone Marrow Neoplasms
1
2012
19
0.370
Why?
Remission Induction
11
2025
764
0.370
Why?
Core Binding Factors
2
2011
12
0.370
Why?
Thrombocytopenia
6
2023
194
0.370
Why?
Cough
1
2012
61
0.360
Why?
Nuclear Proteins
3
2026
757
0.360
Why?
Epigenomics
2
2023
112
0.360
Why?
Dyspnea
1
2012
91
0.360
Why?
Mutation, Missense
1
2013
312
0.330
Why?
Pyridines
4
2023
317
0.330
Why?
Genes, ras
3
2019
97
0.320
Why?
Administration, Oral
7
2026
677
0.310
Why?
Graft vs Host Disease
8
2020
382
0.310
Why?
Stem Cells
1
2013
399
0.310
Why?
Genomics
4
2022
914
0.310
Why?
Indoles
2
2026
340
0.300
Why?
Thrombocythemia, Essential
3
2021
18
0.300
Why?
Myeloid-Lymphoid Leukemia Protein
2
2025
78
0.300
Why?
Janus Kinases
3
2020
25
0.300
Why?
Recurrence
9
2021
1274
0.290
Why?
Electromagnetic Fields
1
2008
27
0.280
Why?
Chromosome Aberrations
5
2023
353
0.280
Why?
Histone-Lysine N-Methyltransferase
2
2025
171
0.280
Why?
Naphthyridines
2
2021
26
0.280
Why?
Prospective Studies
7
2024
4837
0.270
Why?
Anemia
3
2026
135
0.270
Why?
Telomerase
2
2021
69
0.270
Why?
Biomarkers
3
2026
2026
0.260
Why?
Proto-Oncogene Proteins
3
2026
687
0.260
Why?
Tumor Suppressor Protein p53
3
2025
470
0.260
Why?
Survival Analysis
12
2026
1530
0.250
Why?
Polycythemia Vera
3
2013
22
0.250
Why?
Risk Factors
7
2026
6295
0.250
Why?
Piperazines
5
2014
308
0.250
Why?
Pyridones
3
2022
74
0.250
Why?
DNA Repair
1
2008
363
0.240
Why?
Young Adult
18
2025
7598
0.240
Why?
Phenols
1
2026
51
0.240
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2015
150
0.230
Why?
Oligonucleotides
3
2021
93
0.230
Why?
Geriatric Assessment
2
2019
193
0.230
Why?
Leukemia, Myeloid
3
2014
241
0.230
Why?
Hypertension, Pulmonary
2
2026
386
0.220
Why?
Maximum Tolerated Dose
5
2016
265
0.220
Why?
Disease Susceptibility
2
2020
225
0.220
Why?
Eligibility Determination
1
2025
42
0.220
Why?
Antibodies, Monoclonal, Humanized
8
2023
1105
0.210
Why?
Cladribine
1
2004
30
0.210
Why?
Injections, Subcutaneous
1
2024
142
0.210
Why?
Signal Transduction
3
2026
3642
0.210
Why?
Epigenesis, Genetic
4
2014
595
0.210
Why?
Imatinib Mesylate
5
2014
129
0.210
Why?
Cholesterol
1
2026
377
0.200
Why?
CD47 Antigen
1
2024
27
0.200
Why?
Haplotypes
3
2016
657
0.200
Why?
Oleic Acids
1
2023
33
0.200
Why?
Dose-Response Relationship, Drug
8
2019
1949
0.200
Why?
Deoxycytidine
1
2004
218
0.190
Why?
Patient Selection
2
2025
725
0.190
Why?
DNA Methylation
5
2025
735
0.190
Why?
Neoplasm Recurrence, Local
6
2024
1538
0.190
Why?
Cytogenetic Analysis
3
2011
70
0.190
Why?
Hematology
1
2023
37
0.190
Why?
Retrospective Studies
13
2026
11104
0.190
Why?
Myelodysplastic-Myeloproliferative Diseases
1
2022
12
0.190
Why?
Oncogene Proteins, Fusion
2
2014
137
0.180
Why?
Socioeconomic Factors
2
2024
675
0.180
Why?
Adenine Nucleotides
2
2013
57
0.180
Why?
Arabinonucleosides
2
2013
37
0.180
Why?
Proto-Oncogene Proteins c-kit
2
2013
80
0.180
Why?
Antineoplastic Agents, Immunological
1
2025
238
0.180
Why?
Antibodies, Neoplasm
4
2010
87
0.180
Why?
Pneumonia
1
2024
195
0.180
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2026
406
0.180
Why?
Peripheral Blood Stem Cell Transplantation
2
2012
67
0.170
Why?
Nitriles
5
2026
172
0.170
Why?
Antigens, CD34
5
2017
162
0.170
Why?
Biomarkers, Tumor
3
2020
1786
0.170
Why?
Clonal Evolution
1
2020
19
0.160
Why?
Glycine
1
2021
97
0.160
Why?
Animals
11
2026
29045
0.160
Why?
Microbiota
1
2026
473
0.160
Why?
Kaplan-Meier Estimate
6
2020
909
0.160
Why?
Biomedical Research
2
2021
477
0.150
Why?
Etoposide
1
2020
207
0.150
Why?
Drug Resistance, Neoplasm
4
2024
671
0.150
Why?
Allografts
2
2017
221
0.150
Why?
Unrelated Donors
2
2017
50
0.150
Why?
MAP Kinase Kinase 2
1
2019
18
0.150
Why?
Fetal Blood
2
2017
95
0.150
Why?
CD8-Positive T-Lymphocytes
1
2023
701
0.140
Why?
MAP Kinase Kinase 1
1
2019
41
0.140
Why?
Interdisciplinary Communication
1
2019
137
0.140
Why?
Cardiovascular Diseases
1
2026
824
0.140
Why?
Philadelphia Chromosome
1
2018
48
0.140
Why?
Gastrointestinal Microbiome
1
2026
663
0.140
Why?
Immunotherapy
3
2015
831
0.130
Why?
Proto-Oncogene Proteins c-akt
1
2019
369
0.130
Why?
Neutropenia
4
2022
211
0.130
Why?
Preoperative Care
1
2019
420
0.130
Why?
Cell Line, Tumor
4
2026
2913
0.120
Why?
Patient Care Team
1
2019
318
0.120
Why?
Mice
7
2026
12762
0.120
Why?
Adolescent
9
2025
10168
0.120
Why?
Pyrimidinones
2
2019
51
0.120
Why?
Haploidy
1
2016
30
0.120
Why?
Maleimides
1
2016
26
0.120
Why?
Antibodies, Monoclonal
4
2010
1422
0.120
Why?
Hematopoietic Stem Cells
2
2016
330
0.120
Why?
Quality of Life
4
2024
1904
0.120
Why?
Melphalan
3
2011
98
0.120
Why?
Glycogen Synthase Kinase 3
1
2016
72
0.110
Why?
Niacinamide
1
2015
105
0.110
Why?
Karyotype
1
2015
34
0.110
Why?
Heterocyclic Compounds, 3-Ring
1
2016
56
0.110
Why?
Heart Failure
1
2026
1508
0.110
Why?
Cyclin-Dependent Kinase Inhibitor p15
1
2014
22
0.110
Why?
Vidarabine
3
2010
107
0.110
Why?
Thiazoles
1
2015
127
0.110
Why?
Salvage Therapy
2
2007
241
0.110
Why?
Drug Combinations
3
2024
202
0.110
Why?
Quinolones
2
2005
59
0.110
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2014
76
0.110
Why?
HLA Antigens
1
2016
239
0.100
Why?
Graft Survival
3
2016
999
0.100
Why?
Molecular Biology
1
2015
83
0.100
Why?
Receptor, Platelet-Derived Growth Factor beta
1
2014
27
0.100
Why?
Chronic Disease
3
2007
991
0.100
Why?
Acute Disease
5
2022
864
0.100
Why?
Drug Administration Schedule
4
2015
837
0.100
Why?
Neoplasm Staging
3
2015
2087
0.100
Why?
Drug Monitoring
2
2020
167
0.100
Why?
mRNA Cleavage and Polyadenylation Factors
1
2012
3
0.090
Why?
Blood Platelets
1
2013
153
0.090
Why?
Area Under Curve
2
2026
341
0.090
Why?
Phthalazines
1
2013
60
0.090
Why?
Drug Interactions
2
2026
240
0.090
Why?
CD40 Antigens
1
2012
43
0.090
Why?
Chemotherapy-Induced Febrile Neutropenia
2
2026
6
0.090
Why?
Genes, Neoplasm
1
2012
39
0.090
Why?
Up-Regulation
1
2014
742
0.090
Why?
Europe
2
2024
360
0.090
Why?
Alemtuzumab
5
2011
91
0.090
Why?
Disease-Free Survival
5
2015
1196
0.090
Why?
Hematopoiesis
1
2013
187
0.090
Why?
Amino Acid Substitution
1
2013
336
0.090
Why?
Steroids
1
2012
168
0.090
Why?
Neoplasms, Second Primary
2
2012
244
0.090
Why?
Antimitotic Agents
1
2011
3
0.080
Why?
Thionucleotides
2
2008
54
0.080
Why?
Mice, Inbred NOD
2
2022
228
0.080
Why?
CCAAT-Enhancer-Binding Proteins
1
2011
38
0.080
Why?
Comorbidity
4
2018
1037
0.080
Why?
Recombinant Proteins
3
2012
994
0.080
Why?
Karyotyping
1
2011
220
0.080
Why?
Fusion Proteins, bcr-abl
2
2008
111
0.080
Why?
Renal Insufficiency
1
2011
101
0.080
Why?
Dioxygenases
1
2011
92
0.080
Why?
Lymphoma, T-Cell, Cutaneous
1
2010
31
0.080
Why?
Hepatic Veno-Occlusive Disease
1
2010
20
0.080
Why?
Busulfan
1
2010
41
0.080
Why?
Gene Expression
1
2014
1322
0.080
Why?
Terminal Care
1
2011
147
0.080
Why?
Cohort Studies
3
2016
3242
0.080
Why?
DNA Mutational Analysis
1
2011
554
0.070
Why?
Protein Processing, Post-Translational
2
2023
404
0.070
Why?
Graft Rejection
1
2016
1189
0.070
Why?
Myeloid Cells
1
2010
126
0.070
Why?
Drug Evaluation
1
2008
109
0.070
Why?
United States
5
2024
8387
0.070
Why?
Combined Modality Therapy
4
2017
1754
0.070
Why?
Renal Dialysis
1
2011
357
0.070
Why?
Thiosemicarbazones
1
2008
6
0.070
Why?
Methemoglobinemia
1
2008
10
0.070
Why?
Tissue Donors
1
2012
581
0.070
Why?
Gene Expression Regulation, Neoplastic
2
2010
1400
0.070
Why?
Chimerism
2
2020
38
0.070
Why?
Oligodeoxyribonucleotides
1
2008
126
0.070
Why?
Blood Component Removal
1
2008
29
0.070
Why?
Quinoxalines
1
2008
51
0.070
Why?
Histone Deacetylases
1
2008
85
0.070
Why?
Risk Assessment
3
2024
2604
0.070
Why?
DNA (Cytosine-5-)-Methyltransferases
1
2008
63
0.070
Why?
Neoplasm Proteins
3
2020
553
0.070
Why?
Granulocyte Colony-Stimulating Factor
1
2008
158
0.060
Why?
C-Reactive Protein
1
2008
219
0.060
Why?
Interleukin-6
1
2008
283
0.060
Why?
Mycoses
1
2007
46
0.060
Why?
Acute Kidney Injury
1
2011
361
0.060
Why?
Transplantation, Haploidentical
2
2017
29
0.060
Why?
Karnofsky Performance Status
1
2006
43
0.060
Why?
Hematologic Diseases
2
2020
77
0.060
Why?
Histocompatibility Testing
2
2017
145
0.060
Why?
Age Factors
4
2013
1976
0.060
Why?
Transcription, Genetic
1
2011
1136
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
2
2023
213
0.060
Why?
Feasibility Studies
2
2008
818
0.060
Why?
Spiro Compounds
1
2025
24
0.060
Why?
Survival Rate
4
2014
2057
0.060
Why?
Terminology as Topic
1
2007
226
0.050
Why?
Erythropoietin
1
2005
90
0.050
Why?
Environmental Exposure
1
2008
410
0.050
Why?
DNA-Binding Proteins
1
2011
1275
0.050
Why?
Flavonoids
1
2005
86
0.050
Why?
Androgens
1
2005
164
0.050
Why?
Thalidomide
2
2017
57
0.050
Why?
Xenograft Model Antitumor Assays
1
2026
559
0.050
Why?
Protein-Tyrosine Kinases
2
2021
305
0.050
Why?
Societies, Medical
2
2021
687
0.050
Why?
Propensity Score
1
2025
218
0.050
Why?
Linoleic Acids, Conjugated
1
2023
10
0.050
Why?
Interleukin-3 Receptor alpha Subunit
1
2023
4
0.050
Why?
Dairy Products
1
2023
13
0.050
Why?
Red Meat
1
2023
12
0.050
Why?
Hemoglobins
1
2024
197
0.050
Why?
Endpoint Determination
1
2024
65
0.050
Why?
Piperidines
1
2005
177
0.050
Why?
Fatty Acids, Volatile
1
2023
35
0.050
Why?
Milk
1
2023
56
0.050
Why?
Cyclic AMP Response Element-Binding Protein
1
2023
64
0.050
Why?
Sheep
1
2023
204
0.050
Why?
Transplantation, Autologous
2
2019
398
0.050
Why?
bcl-X Protein
1
2023
57
0.050
Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2023
44
0.050
Why?
Fatigue
1
2004
187
0.050
Why?
Cyclopentanes
1
2023
28
0.050
Why?
Angiogenesis Inhibitors
1
2005
281
0.050
Why?
Quinuclidines
1
2023
11
0.050
Why?
Blood Transfusion
1
2024
179
0.050
Why?
Cyclic AMP-Dependent Protein Kinases
1
2023
119
0.050
Why?
Cattle
1
2023
398
0.050
Why?
Cyclic AMP
1
2023
277
0.050
Why?
Drug Approval
2
2015
68
0.050
Why?
Cell- and Tissue-Based Therapy
1
2023
65
0.050
Why?
Clinical Trials, Phase I as Topic
1
2023
154
0.050
Why?
Receptors, G-Protein-Coupled
1
2023
176
0.040
Why?
World Health Organization
1
2022
125
0.040
Why?
Echocardiography
1
2026
788
0.040
Why?
Mice, SCID
1
2022
278
0.040
Why?
Phenotype
2
2020
2673
0.040
Why?
Social Determinants of Health
1
2024
149
0.040
Why?
Bacteria
1
2026
547
0.040
Why?
Ketoglutaric Acids
1
2021
15
0.040
Why?
Acetyl-CoA C-Acetyltransferase
1
2021
7
0.040
Why?
Infusions, Intravenous
2
2015
403
0.040
Why?
Prevalence
2
2018
1396
0.040
Why?
NADP
1
2021
48
0.040
Why?
Primary Cell Culture
1
2021
84
0.040
Why?
Clone Cells
1
2021
223
0.040
Why?
Acetylation
1
2021
151
0.040
Why?
Single-Blind Method
1
2021
160
0.040
Why?
Bone Marrow
2
2016
419
0.040
Why?
DNA-Cytosine Methylases
1
2020
4
0.040
Why?
Capsules
1
2020
39
0.040
Why?
Daunorubicin
1
2020
77
0.040
Why?
Pilot Projects
2
2015
978
0.040
Why?
Long Interspersed Nucleotide Elements
1
2020
14
0.040
Why?
Least-Squares Analysis
1
2020
50
0.040
Why?
Drug Synergism
1
2021
317
0.040
Why?
Risk
2
2012
662
0.040
Why?
Hematopoietic Stem Cell Mobilization
2
2012
52
0.040
Why?
Cell Proliferation
1
2026
1801
0.040
Why?
Lysine
1
2021
170
0.040
Why?
Illinois
2
2012
531
0.040
Why?
Rats
1
2026
4079
0.040
Why?
Health Planning Guidelines
1
2019
25
0.040
Why?
Hospitalization
1
2026
993
0.040
Why?
Cross-Over Studies
1
2020
394
0.040
Why?
Health Plan Implementation
1
2019
62
0.040
Why?
Diamines
1
2019
9
0.040
Why?
Standard of Care
1
2019
71
0.040
Why?
Gastrointestinal Diseases
1
2020
156
0.040
Why?
Polymorphism, Single Nucleotide
2
2021
2577
0.040
Why?
Phosphorylation
1
2021
1148
0.040
Why?
Tablets
1
2020
137
0.030
Why?
Protein Biosynthesis
1
2021
393
0.030
Why?
Safety
1
2019
138
0.030
Why?
Preoperative Period
1
2018
103
0.030
Why?
Time Factors
2
2021
5586
0.030
Why?
Early Detection of Cancer
2
2015
563
0.030
Why?
Lymphocyte Depletion
1
2017
103
0.030
Why?
Protein Binding
1
2021
1564
0.030
Why?
Cause of Death
1
2018
279
0.030
Why?
Palliative Care
1
2019
291
0.030
Why?
Clinical Decision-Making
1
2019
306
0.030
Why?
Apoptosis
1
2023
1754
0.030
Why?
Predictive Value of Tests
2
2014
1792
0.030
Why?
Retreatment
1
2016
106
0.030
Why?
Incidence
2
2011
1798
0.030
Why?
Ranitidine
1
2016
8
0.030
Why?
Anti-Ulcer Agents
1
2016
22
0.030
Why?
Histocompatibility
1
2016
71
0.030
Why?
Organ Size
1
2016
370
0.030
Why?
Immunosuppressive Agents
2
2011
1021
0.030
Why?
U937 Cells
1
2015
32
0.030
Why?
Pemetrexed
1
2016
76
0.030
Why?
Postoperative Complications
1
2007
2719
0.030
Why?
Leukocyte Count
1
2016
215
0.030
Why?
Liver Function Tests
1
2015
95
0.030
Why?
Gene Expression Regulation, Leukemic
1
2015
100
0.030
Why?
Federal Government
1
2015
28
0.030
Why?
Financing, Government
1
2015
26
0.030
Why?
Leukocytes, Mononuclear
1
2016
213
0.030
Why?
Mortality
1
2016
160
0.030
Why?
Pandemics
1
2021
923
0.030
Why?
Neoplasm Grading
1
2016
425
0.030
Why?
Bone Marrow Cells
1
2016
269
0.030
Why?
Carboplatin
1
2016
331
0.030
Why?
Rare Diseases
1
2015
75
0.030
Why?
Neutrophils
1
2016
346
0.030
Why?
beta Catenin
1
2016
269
0.030
Why?
Research Support as Topic
1
2015
97
0.030
Why?
Tumor Cells, Cultured
1
2015
1029
0.030
Why?
Antineoplastic Agents, Hormonal
1
2015
161
0.030
Why?
United States Food and Drug Administration
1
2015
165
0.030
Why?
RNA, Small Interfering
1
2015
573
0.020
Why?
Platelet Count
1
2013
94
0.020
Why?
Cancer Vaccines
1
2015
168
0.020
Why?
Proportional Hazards Models
2
2006
925
0.020
Why?
Translocation, Genetic
1
2014
246
0.020
Why?
Receptors, Vascular Endothelial Growth Factor
1
2013
58
0.020
Why?
Immunoglobulin Isotypes
1
2013
33
0.020
Why?
Pneumococcal Vaccines
1
2013
32
0.020
Why?
Alleles
1
2016
1163
0.020
Why?
Lymphocyte Count
1
2013
99
0.020
Why?
Lymphocyte Subsets
1
2013
71
0.020
Why?
T-Lymphocytes
1
2020
1335
0.020
Why?
Virus Diseases
1
2013
83
0.020
Why?
Patient Outcome Assessment
1
2013
90
0.020
Why?
Drugs, Investigational
1
2012
36
0.020
Why?
Vascular Diseases
1
2013
119
0.020
Why?
Hospice Care
1
2011
40
0.020
Why?
Multicenter Studies as Topic
1
2012
195
0.020
Why?
Interferon-alpha
1
2012
191
0.020
Why?
Adult Stem Cells
1
2011
31
0.020
Why?
DNA, Neoplasm
1
2012
267
0.020
Why?
Double-Blind Method
1
2015
1793
0.020
Why?
Primary Prevention
1
2011
93
0.020
Why?
Child
2
2014
7771
0.020
Why?
Diarrhea
1
2012
180
0.020
Why?
Educational Status
1
2011
206
0.020
Why?
Fatal Outcome
1
2011
295
0.020
Why?
Secondary Prevention
1
2011
194
0.020
Why?
Health Care Reform
1
2011
79
0.020
Why?
Metabolic Clearance Rate
1
2010
118
0.020
Why?
Liver
1
2015
1231
0.020
Why?
Radiotherapy, Adjuvant
1
2011
325
0.020
Why?
Glomerular Filtration Rate
1
2011
304
0.020
Why?
Research
1
2011
258
0.020
Why?
Receptors, Antigen, T-Cell
1
2013
454
0.020
Why?
Family
1
2012
330
0.020
Why?
Tacrolimus
1
2011
376
0.020
Why?
Chemotherapy, Adjuvant
1
2011
527
0.020
Why?
Nervous System Diseases
1
2011
169
0.020
Why?
Polyethylene Glycols
1
2012
383
0.020
Why?
Health Policy
1
2011
218
0.020
Why?
Lymphoma, Non-Hodgkin
1
2011
262
0.020
Why?
Down-Regulation
1
2010
529
0.020
Why?
Follow-Up Studies
1
2016
4049
0.020
Why?
Myeloablative Agonists
1
2008
38
0.020
Why?
DNA (Cytosine-5-)-Methyltransferase 1
1
2008
20
0.020
Why?
Half-Life
1
2008
90
0.020
Why?
Stereoisomerism
1
2008
102
0.020
Why?
Filgrastim
1
2008
56
0.020
Why?
Practice Guidelines as Topic
1
2015
1116
0.020
Why?
Obesity
1
2015
1079
0.020
Why?
Treatment Failure
1
2008
300
0.020
Why?
Infant
1
2014
3368
0.020
Why?
Antifungal Agents
1
2007
127
0.020
Why?
Health Services Accessibility
1
2011
548
0.020
Why?
Liver Diseases
1
2008
250
0.020
Why?
Child, Preschool
1
2014
4053
0.010
Why?
Infusion Pumps
1
2005
26
0.010
Why?
Inflammation
1
2012
1134
0.010
Why?
Healthcare Disparities
1
2011
558
0.010
Why?
Gene Expression Profiling
1
2011
1572
0.010
Why?
MicroRNAs
1
2010
609
0.010
Why?
Length of Stay
1
2008
889
0.010
Why?
Biological Availability
1
2004
86
0.010
Why?
Statistics, Nonparametric
1
2004
304
0.010
Why?
Prostatic Neoplasms
1
2015
1846
0.010
Why?
Blotting, Western
1
2004
779
0.010
Why?
Analysis of Variance
1
2004
890
0.010
Why?
Genome-Wide Association Study
1
2011
1863
0.010
Why?
Genetic Predisposition to Disease
1
2011
2588
0.010
Why?
RNA, Messenger
1
2008
2076
0.010
Why?
Tomography, X-Ray Computed
1
2011
2680
0.010
Why?
Breast Neoplasms
1
2015
3303
0.010
Why?
Odenike's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (456)
Explore
_
Co-Authors (89)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_